HOUSTON, Jan. 7, 2022 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"),
a biopharmaceutical company specializing in the development of
novel treatments for primary and metastatic cancers in the brain
and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS
Pharmaceuticals, will present at the virtual H.C. Wainwright
BioConnect Conference taking place January
10-13, 2022.
A video webcast of the presentation will be accessible for
viewing on-demand beginning on Monday,
January 10, 2022, at 7:00 AM
ET for those registered for the event and will be available
on the Events page in the Investors section of the Company's
website (www.cnspharma.com). The webcast replay will be archived
for 90 days following the event.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its
WP1244 drug technology, which utilizes anthracycline and
distamycin-based scaffolds to create small molecule agents and is
believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is evaluating the use of WP1244 in the treatment of
brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-hc-wainwright-bioconnect-conference-301456183.html
SOURCE CNS Pharmaceuticals, Inc.